Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana prior auth list (SC) Coverage Update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana Dual Integrated South Carolina prior authorization and notification list (medications/services)

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governance of prior authorization and notification requirements for medications (including professionally administered drugs) and related services for Humana Dual Integrated (HMO D-SNP) members in South Carolina; affects participating providers, delegated risk networks, and providers requesting advance coverage determinations.

    Policy Summary
    PayerHumana
    PolicyHumana Dual Integrated South Carolina prior authorization and notification list (medications/services)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before providing or administering listed medications and related services (unless urgent/emergent).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90+medication entries (partial)
    3submission methods
    90 daysactive treatment grace
    866-461-7273phone for medication ACDs/PAs
    NDC requiredNDC billing requirement

    Coverage Criteria and Medication List

    Prior authorization and step therapy criteria

    Services and medications require prior authorization and must meet Medicare medical necessity criteria; step therapy may apply for certain Part B medications.

    Medications listed require prior authorization before administration except urgent or emergent services.
    Services and items must meet Centers for Medicare & Medicaid Services (CMS) Medicare coverage guidelines and be medically necessary.
    Step therapy may apply where indicated; a trial of a Humana-preferred drug (including cross‑benefit trials across Part B and Part D) may be required per Humana's Part B Step Therapy Preferred Drug List (PDL).

    Medication prior authorization/notification list (partial)

    Medication entries in this document require prior authorization or notification; each entry shows brand, generic, and billing codes and may include symbols denoting special requirements.

    Policy Summary
    PayerHumana
    PolicyHumana Dual Integrated South Carolina prior authorization and notification list (medications/services)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before providing or administering listed medications and related services (unless urgent/emergent).
    SourceLink
    On This Page
    Coverage Criteria and Medication ListBilling Codes and Coding RulesProvider Submission, Authorization, and Operational NotesDefinitions and Legend
    Each medication entry includes: Brand name, Generic name, and Billing Codes (HCPCS/J-codes or other codes) as shown in the list.
    Entries may include annotation symbols: '*' = new preauthorization requirement; '†' = new-to-market addition; '‡' = shared HCPCS/NOC codes require a corresponding NDC on claims; '**' = step therapy required.
    Providers should consult the entry annotations to determine if step therapy, NDC billing, transplant routing, or other special handling applies.

    Coverage and preauthorization criteria (partial)

    Listed drugs require prior authorization or notification as indicated; certain codes require an NDC on claims; step therapy or transplant review may apply where noted.

    Prior authorization is required for medications listed on the Humana Dual Integrated (HMO D-SNP) South Carolina prior authorization and notification list.
    All shared HCPCS codes and not‑otherwise‑classified codes (e.g., C9399, J3490, J3590) require a corresponding National Drug Code (NDC) to be billed on all claims when indicated with the '‡' annotation.
    Step therapy applies to products annotated with '**'; preauthorization will require documentation of trial/failure of a Humana‑preferred drug per the Part B Step Therapy PDL.

    Transplant review routing

    • Items annotated with '††' are transplant‑related and preauthorization requests will be reviewed by the Humana National Transplant Network.
    • Transplant preauthorization submissions may be sent by fax to 502-508-9300, phone 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. CT), or email transplant@humana.com.
    The list contains multiple individual drug entries (brand/generic/billing codes) and related annotations; providers must follow the specific entry instructions for submission and billing.

    Prior authorization list and procedural notes (part 4)

    Listed products require prior authorization; some require step therapy or Humana National Transplant Network review. Billing instructions and special annotations are shown with each entry.

    Products listed in this section require prior authorization as indicated in the entry; follow the specific billing code(s) shown for each product.
    Entries marked with '**' require step therapy through a Humana‑preferred drug as part of preauthorization.
    Entries marked with '‡' indicate shared HCPCS or not‑otherwise‑classified codes that require a corresponding NDC to be billed on claims.
    Entries marked with '††' (transplant related) will be routed to Humana National Transplant Network for review; use the transplant submission channels provided in the list.
    Operational billing note: Providers should use the specific HCPCS/J codes listed for each product and include NDCs where the shared/NOC annotation applies to ensure proper claim adjudication.

    Billing Codes and Coding Rules

    Sample HCPCS/CPT/J-codes listedHCPCSCovered
    Q2055Abecma billing code
    J9264Abraxane billing code
    J3262Actemra IV billing code
    Additional HCPCS/J-codesHCPCSCovered
    J9035Avastin (oncology use) billing code
    J3145Aveed billing code
    Examples of listed HCPCS/CodesHCPCS
    J9019Crisantaspase (Erwinase)
    J7323Euflexxa (sodium hyaluronate)
    Additional HCPCS/CodesHCPCS
    J9271Keytruda (pembrolizumab)
    J2507Krystexxa (pegloticase)
    Sample HCPCS/J-codes present in segmentHCPCS | CPT | mixed
    C9399, J3490, J3590Example shared/unspecified HCPCS and J-codes used for multiple listed drugs
    J2267Billing code example for mirikizumab-mrkz (Omvoh IV)
    Blood-clotting factor billing codesHCPCSCovered
    J7192Advate — antihemophilic factor, human recombinant
    J7207Adynovate — antihemophilic factor [recombinant], PEGylated
    Listed HCPCS/J-codes for blood-clotting and specialty drugsHCPCSCovered
    J7192Advate / antihemophilic factor; appears multiple times for different products
    J7207Adynovate
    J7210Afstyla
    J7173Alhemo
    J7186Alphanate
    J7193AlphaNine SD
    J7201Alprolix
    J7214Altuviiio
    J7198Feiba NF
    J1411Hemgenix
    1–10 of 39
    1/4
    Maximum diagnosis codes per authorization request
    Maximum diagnosis codesUp to 6 diagnosis codes per authorization request
    Required fields contextHCPCS code(s) and diagnosis codes (primary and secondary) should be included on requests
    PurposeSubmitting all relevant clinical and coding information helps expedite determination
    NDC requirement for shared HCPCS and NOC codes
    NDC billing requirementAll shared HCPCS codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims
    Examples of affected codesIncludes shared/unspecified codes such as C9399, J3490, J3590 (and other shared HCPCS/J-codes)
    Implication for claimsProviders must include the corresponding NDC on claim submissions for listed medications using shared or NOC codes

    Provider Submission, Authorization, and Operational Notes

    Prior Authorization

    Prior authorization required

    Prior authorization is required for the medications listed and for certain services. Providers must obtain advance approval from Humana before providing or administering these medications or services. Failure to obtain required prior authorization may result in financial penalties to the practice, retrospective medical necessity review, and denial of payment per the member's Evidence of Coverage and provider contract.

    • Prior authorization (preauthorization, precertification) = advance approval from the plan prior to service or medication administration.
    • Services must meet Medicare/CMS coverage guidelines and be medically necessary.
    • Investigational/experimental procedures and devices are generally not covered.
    Note

    How to submit prior authorization / ACD for medications

    Except where noted in the prior authorization list, providers may submit prior authorization requests or advance coverage determinations (ACDs) for medications using one of the three methods below. CoverMyMeds submissions and fax/phone requests are monitored during stated business hours; include clinical documentation as needed.

    • Online: CoverMyMeds (http://www.covermymeds.com/)
    • Phone: 866-461-7273 (TTY: 711), Monday - Friday, 8 a.m. - 11 p.m., Eastern time
    • Fax: 888-447-3430 (request forms available on Humana's prior authorization for professionally administered drugs website)
    Note

    Delegation and applicability

    Providers participating in an IPA or other delegated risk network remain subject to Humana's prior authorization list (PAL). Delegated entities should follow their IPA/risk network's instructions for processing requests and may be required to submit requests through delegated workflows.

    • Humana MA HMO and HMO POS: full PAL applies.
    • Delegated providers: refer to your IPA or risk network for request processing guidance.
    Denial Risk

    Consequences of missing prior authorization

    If prior authorization is not obtained when required, services or medications may be denied or result in reduced benefits for the member. Humana may perform retrospective medical necessity review on services provided without prior authorization. Providers should verify benefits and prior authorization requirements prior to providing services to avoid claims payment issues.

    • Potential consequences: financial penalties, reduced patient benefits, retrospective medical necessity review, denial of payment.
    • To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member’s enrollment for active courses of treatment started prior to enrollment — include modifier per Humana Medicare Advantage Payment Policy or supporting medical records when applicable.
    Note

    Special indicators and exceptions (legend)

    Certain medications and codes on the list are flagged with symbols that indicate special handling or requirements. Review these indicators before submitting a request and ensure required supporting information (such as corresponding NDCs for shared HCPCS codes) is included with claims and authorization requests.

    • * = New preauthorization requirement
    • † = New-to-market drug addition
    • ‡ = All shared HCPCS and NOC codes require a corresponding NDC to be billed on all claims
    • ** = Step therapy required through a Humana-preferred drug as part of preauthorization
    • †† = Preauthorization requests for transplant-related items will be reviewed by the Humana National Transplant Network (see transplant submission contacts)
    Note

    How to request prior authorization and submission contacts

    Humana National Transplant Network reviews transplant-related preauthorization requests. Submit transplant requests by fax, phone, or email using the contacts below. For other preauthorization submissions, use the general CoverMyMeds/phone/fax methods listed above. Include NDCs when billing shared HCPCS or NOC codes and follow step therapy requirements where indicated.

    • Humana National Transplant Network (transplant products): Fax to 502-508-9300; Phone 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time; Email: transplant@humana.com
    • For non-transplant medication prior authorizations: CoverMyMeds, Phone 866-461-7273 (TTY 711), Fax 888-447-3430
    • Include corresponding NDC on claims when using shared HCPCS or NOC codes; failure to include NDCs may affect claim payment.
    Billing Rule

    General preauthorization and billing notes

    Operational and billing notes to ensure proper processing and payment: follow Humana coverage and claims payment policies; include required modifiers for active courses of treatment when applicable; comply with step therapy requirements and bill NDCs for shared HCPCS/NOC codes. Access Humana's provider websites for request forms, Part B Step Therapy Preferred Drug List, Medical and Pharmacy Coverage Policies, and specialty/mail-order pharmacy listings.

    • Follow Humana's Medicare Advantage Payment Policy (CP2023011) modifier guidance when submitting claims for active courses of treatment started prior to enrollment.
    • Step therapy: some medications require trial of Humana-preferred drugs (see Part B Step Therapy PDL on Humana's provider prior authorization notification lists website).
    • If providers do not stock a preferred medication, a pharmacy may ship the preferred product to the office; see Humana's mail-order and specialty pharmacy resources.
    • Access request forms and fax forms on Humana's prior authorization for professionally administered drugs website.

    Definitions and Legend

    Prior authorization
    DefinitionPrior authorization is a process through which the healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.
    ScopeApplies to medications delivered in office, clinic, outpatient or home settings that require authorization before being provided or administered
    Medicare alignmentServices must be provided according to Medicare coverage guidelines and medical necessity criteria
    Part B Step Therapy PDL
    DefinitionPart B Step Therapy Preferred Drug List (PDL) identifies preferred and nonpreferred medications and cross-benefit step therapy strategies across Part B and Part D
    UsePDL provides background information and a comprehensive list of preferred/nonpreferred medications to guide step therapy requirements
    ReferenceProviders should review the Part B Step Therapy PDL in conjunction with Humana's coverage policies available on Humana's Medical and Pharmacy Coverage Policies website
    "**" (double asterisk)
    Symbol meaning'**' indicates step therapy required through a Humana-preferred drug as part of preauthorization
    Operational impactPreauthorization will require documentation of trial/failure of the Humana-preferred agent where '**' is indicated
    LocationThe '**' indicator appears next to affected medication entries on the Medicare PAL
    "‡" (dagger)
    Symbol meaning'‡' indicates shared HCPCS/NOC codes require a corresponding NDC to be billed on all claims
    ExamplesShared/unspecified codes referenced include C9399, J3490, J3590 and similar shared HCPCS/J-codes
    Claims requirementWhen '‡' is shown, providers must include the corresponding NDC on claim submissions for the listed product
    *, †, †† symbols
    '*'Indicates a new preauthorization requirement
    '†'Indicates a new-to-market drug addition
    '††'Indicates preauthorization requests for specified items will be reviewed by the Humana National Transplant Network
    Legend
    *New preauthorization requirement
    †New-to-market drug addition
    ‡Shared HCPCS/Codes require corresponding NDC to be billed on claims
    **Step therapy required through a Humana-preferred drug as part of preauthorization
    Transplant preauthorization process
    ReviewerPreauthorization reviews for transplant-related products are conducted by the Humana National Transplant Network
    Submission channelsRequests can be submitted by fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. CT), or by email to transplant@humana.com
    ScopeTransplant-network review applies to items annotated for transplant review (e.g., '††') on the prior authorization list
    Step therapy
    DefinitionStep therapy requires trial of a Humana-preferred drug (where indicated) before authorization of an alternative agent
    Cross-benefit noteSome step therapy strategies may require trials across Medicare Part B and Part D per the Part B Step Therapy PDL
    DocumentationPreauthorization must include evidence of prior trials or clinical rationale when step therapy is applicable
    HCPCS/NDC billing requirement
    Billing requirementShared and not otherwise classified (NOC) HCPCS codes require a corresponding NDC on all claims for listed products
    Affected codesExamples include C9399, J3490, J3590 and other shared/unspecified HCPCS or J-codes
    Provider actionEnsure NDC is included when submitting claims for medications billed with shared or NOC HCPCS codes
    Humana National Transplant Network
    RoleHumana National Transplant Network reviews preauthorization requests for specified transplant-related products
    Contact summaryFax: 502-508-9300; Phone: 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. CT); Email: transplant@humana.com
    When to useUse the transplant-network submission channels for items annotated with transplant review indicators on the PAL